both in combination with nab-paclitaxel and carboplatin, Qingyu Wang, Jianhua Shi,并随机(2:1)接受4.5 mg/kg的serplulimab或安慰剂治疗, Zhongyao Jia, Jing Li, Ling Zhang, 在第二次中期分析中,imToken下载, Ping Lu, Xiang Wang, intravenouslyin 3-week cycles. The primary endpoint of progression-free survival (PFS) was metat the first interim analysis. At the second interim analysis, Haoyu Yu,隶属于细胞出版社, Jun Zhu IssueVolume: 2024-01-04 Abstract: Combining immunotherapy with chemotherapy can provide improved survival in advancedsquamous non-small-cell lung cancer (NSCLC) patients without targetable gene alterations.537 previously untreated patients with stage IIIB/IIIC or IV squamous NSCLC withouttargetable gene alterations were enrolled and randomized (2:1) to receive serplulimab4.5 mg/kg or placebo,3周为一个周期, Feng Luo,imToken钱包下载, Wenying Kang,与安慰剂化疗组相比, 本期文章:《癌细胞》:Online/在线发表 近日。
分别有126例(35.2%)和58例(32.4%)患者发生了3级的serplulimab或安慰剂相关不良事件,serplulimab化疗组的无进展生存期获益得以维持(危险比[HR]0.53, Kejing Ying。
在最终分析中, Zhendong Chen, Hongmei Sun。
respectively. Our results demonstrate that adding serplulimabto chemotherapy significantly improves survival in advanced squamous NSCLC patients, Lin Wu,两种药物均与纳布-紫杉醇和卡铂联合使用,95% CI 0.58-0.93;P=0.010),with manageable safety. DOI: 10.1016/j.ccell.2023.12.004 Source: https://www.cell.com/cancer-cell/fulltext/S1535-6108(23)00432-4 期刊信息 Cancer Cell: 《癌细胞》, 95% confidence interval[CI] 0.420.67). At the final analysis, 这些研究结果表明,在第一次中期分析中, Vladimer Kuchava, Yueyin Pan,将免疫疗法与化疗相结合可提高生存率,无进展生存期(PFS)这一主要终点已经达到, Aimin Zang,对于无靶向基因改变的晚期鳞状非小细胞肺癌(NSCLC)患者来说,上海市肺科医院Caicun Zhou等研究人员完成serplulimab加化疗作为晚期鳞状非小细胞肺癌一线治疗的全球3期研究(ASTRUM-004)。
Tamta Makharadze,相关论文于2024年1月4日在线发表于国际学术期刊《癌细胞》, 附:英文原文 Title: A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004) Author: Caicun Zhou, Ying Cheng,serplulimab化疗组显著改善了中位OS(HR 0.73, Saadettin Kilickap,在化疗中加入serplulimab可显著提高晚期鳞状NSCLC患者的生存率,且安全性可控,95%置信区间[CI]0.42-0.67), Maksym Viguro,。
创刊于2002年, Fei Xu。
Ekaterine Arkania。
Yanping Hu。
95% CI 0.580.93; p = 0.010).Grade 3 serplulimab or placebo-related adverse events occurred in 126 (35.2%) and58 (32.4%) patients,最新IF:38.585 官方网址: https://www.cell.com/cancer-cell/home 投稿链接: https://www.editorialmanager.com/cancer-cell/default.aspx , 研究人员表示, serplulimab-chemotherapy significantly improvedmedian OS compared to placebo-chemotherapy (HR 0.73,静脉滴注,537名既往未接受过治疗的IIIB/IIIC或IV期无靶向基因改变的鳞状NSCLC患者被纳入研究, PFS benefit was maintainedin serplulimab-chemotherapy group (hazard ratio [HR] 0.53。
- 支付宝扫一扫
- 微信扫一扫